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Abstract The axon-protective Wallerian degeneration slow
(WLDS) protein can ameliorate the decline in axonal ATP
levels after neurite transection. Here, we tested the hypothesis
that this effect is associated with maintenance of mitochon-
drial respiration and/or glycolysis. We used isolated neurites
of superior cervical ganglion (SCG) cultures in the Seahorse
XF-24 Metabolic Flux Analyser to determine mitochondrial
respiration and glycolysis under different conditions. We ob-
served that both mitochondrial respiration and glycolysis de-
clined significantly during the latent phase ofWallerian degen-
eration. WLDS partially reduced the decline both in glycolysis
and in mitochondrial respiration. In addition, we found that
depleting NAD levels in uncut cultures led to changes in
mitochondrial respiration and glycolysis similar to those res-
cued by WLDS after cut, suggesting that the maintenance of
NAD levels in WldS neurites after axonal injury at least par-
tially underlies the maintenance of ATP levels. However, by
using another axon-protective mutation (Sarm1−/−), we could
demonstrate that rescue of basal ECAR (and hence probably
glycolysis) rather than basal OCR (mitochondrial respiration)
may be part of the protective phenotype to delay Wallerian
degeneration. These findings open new routes to study glycol-
ysis and the connection between NAD and ATP levels in axon
degeneration, which may help to eventually develop therapeu-
tic strategies to treat neurodegenerative diseases.
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Abbreviations
DIV Days in vitro
ECAR Extracellular acidification rate
NAMPT Nicotinamide phosphoribosyltransferase
NMN Nicotinamide mononucleotide
NMNAT Nicotinamide adenylyltransferase
OCR Oxygen consumption rate
Ube4b Ubiquitin ligase E4b Superior cervical ganglion
SCG Superior cervical ganglion
WLDS Wallerian degeneration slow protein
Introduction
Axons depend on the supply of energy in form of ATP to fuel
important processes such as axonal transport, maintenance of
the resting membrane potential and neurotransmitter release.
Failure to generate sufficient ATP results in irreversible axon
damage (Shen and Goldberg 2012). Axon degeneration is also
often associated with energy depletion caused by mitochon-
drial dysfunction (Court and Coleman 2012), reduction in
substrate availability (Ebneter et al. 2011; Lee et al. 2012;
Viader et al. 2011) and/or excessive energy consumption (Stys
2005). In many neurological disorders, axon degeneration is
an early event preceding neuronal cell body loss (Coleman
and Freeman 2010). Understanding the mechanisms that un-
derlie axon degeneration is therefore an important step towards
developing novel therapeutic strategies for these diseases.
One important tool to study molecular mechanisms under-
lying axon degeneration is the Wallerian degeneration slow
(WldS) mutant mouse, in which axon degeneration after injury
is significantly delayed (Lunn et al. 1989) and in which axons
are protected against degeneration in a variety of experimental
models of neurological disorders such as models for multiple
sclerosis (Kaneko et al. 2006), Parkinson’s disease (Sajadi
et al. 2004; Hasbani and O’Malley 2006; Antenor-Dorsey
and O’Malley 2012) and glaucoma (Howell et al. 2007).
The WldS phenotype is caused by expression of the chimeric
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WLDS protein, which consists of the 70 amino acids of the N-
terminal region of the ubiquitin ligase E4b (Ube4b) linked via
18 amino acids to full-length nicotinamide mononucleotide
adenylyltransferase 1 (NMNAT1) (Coleman et al. 1998). Both
parts of the WLDS protein are important for the axon-
protective phenotype (Coleman and Freeman 2010). WLDS
is thought to act in the axon through its NMNAT activity,
converting nicotinamide mononucleotide (NMN) and ATP to
NAD and PPi.
It has been shown that WLDS can ameliorate the decline in
NAD and ATP levels after axonal injury in primary culture
(Wang et al. 2005), but the exact mechanisms through which
ATPmaintenance fails are not yet fully understood. Therefore,
the aim of the present study was to investigate cellular ener-
getics after axonal injury and the influence of WLDS expres-
sion and NAD on these processes.
Material and Methods
Animals
All animal work was carried out in accordance with the UK
Animals (Scientific Procedures) Act, 1986, under Project
Licences 80/2254 and 70/7620 and was approved by the
Babraham Institute Animal Welfare, Experimentation and
Ethics Committee. C57BL/6JBabr and homozygous C57BL/
6OlaHsd-Wld (WldS) mice were originally obtained from
Harlan UK (Bicester, UK) and maintained as a long-term
breeding colony at the Babraham Institute. Sarm1−/− mice
(Kim et al. 2007) were obtained from ProfessorMarc Freeman
(University of Massachusetts Medical School, Worcester,
MA, USA) with permission from Professor Aihao Ding (Weill
Cornell Medical College, New York, NY, USA).
Cell Culture
Superior cervical ganglia (SCGs) were dissected from P0-P3
mouse pups. In each experiment, three cleaned explants were
placed in the centre of each well in a 24-well plate (Seahorse
Bioscience, North Billerica, MA, USA) pre-coated with poly-
L-lysine (20 μg/ml for 1–2 h; Sigma) and laminin (20 μg/ml
for 1–2 h; Sigma) to ensure the same amount of material in
each well, and similar degrees of neurite outgrowth were
confirmed for each genotype. Explants were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) with
4,500 mg/l glucose and 110 mg/l sodium pyruvate (Sigma),
2 mM glutamine, 1 % penicillin/streptomycin, 100 ng/ml 7S
NGF (all Invitrogen), and 10 % foetal bovine serum (Sigma)
at 37 °C and 5 % CO2. To reduce proliferation and viability of
small numbers of non-neuronal cells, 4 μM aphidicolin
(Calbiochem) was added. Cultures were used after 6 days
in vitro.
HPLC Analysis
NAD levels were determined using reversed phase HPLC
as described before (Balducci et al. 1995). Briefly, SCG
explant cultures treated for 24 h with DMSO or 100 nM
FK866 were lysed, acidified with HClO4 and then
neutralised with K2CO3 before loading on a LC18
Supelcosil column.
Seahorse XF-24 Metabolic Flux Analysis
On the day of analysis, the medium of the cells was changed
to unbuffered DMEM (modified DMEM supplemented
with 25 mM glucose and 1 mM sodium pyruvate (both
Sigma), pH 7.4). SCG explants were then incubated in a
non-CO2 incubator at 37 °C for 30 min before cutting the
neurites and removing the cell body mass. Remaining
neurites were either measured straight after cut (early after
cut) or left for another 140 min in the incubator before
measuring (late after cut). As transected neurites degenerate
after more than 4 h (Gilley and Coleman 2010), this ensures
that the 80-min measurement period is complete during the
time when distal neurites remain continuous. In some cases,
neurites and cell bodies were not separated but treated with
100 nM of the specific NAMPT inhibitor FK866 (kind gift
fromRTI International, Research Park, NC, USA) 24 h prior
to measurements. After a 20-min calibration step in the
Seahorse XF-24 analyser, the analysis was started with a
pattern of 2-min mixing, 2-min waiting, and 2-min measur-
ing. Three baseline measurements of oxygen consumption
rate (OCR) and extracellular acidification rate (ECAR) were
taken before sequential injection of mitochondrial inhibi-
tors. After each addition of mitochondrial inhibitor, three
readings were taken before injection of the subsequent
inhibitor. The mitochondrial inhibitors were used in the
following order: oligomycin (2 μM), FCCP (8 μM), and
rotenone (200 nM) together with antimycin (8μM) (all from
Sigma). OCR and ECAR were automatically calculated and
recorded by the Seahorse XF-24 software. As some proteins
are rapidly degraded following neurite transection (Gilley
and Coleman 2010; Shen et al. 2013), readings were not
normalised to protein levels, but rather, triplicate samples
were run in each of up to six experiments and similar growth
of neurites was confirmed.
Statistical Analysis
All OCR and ECAR graphs were analysed using a two-way
repeated measures ANOVA considering the different time and
treatment/genotype as factors and matching samples for time
point and day of experiment. This meant that day-to-day
experimental variation was taken into account. However, for
the sake of clarity, this matching was not reflected in the
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graphs, which simply display mean±SEM for data col-
lected on different days.
Results
ATP levels significantly decline after axonal injury in primary
culture neurites (Wang et al. 2005), but whether mitochondrial
respiration, glycolysis or both are primarily affected is un-
known. To investigate these processes, we used the Seahorse
XF-24 Metabolic Flux Analyser to determine changes in
oxygen consumption (parameter for mitochondrial respira-
tion) and free protons (parameter for glycolysis) after axonal
injury but before degeneration occurred. In addition to basal
respiration and basal glycolysis, this technique enables the
measurements of further parameters of mitochondrial respira-
tion and glycolysis through serial injection of mitochondrial
inhibitors such as oligomycin, FCCP, rotenone and antimycin.
Oligomycin inhibits the ATP synthase allowing the determi-
nation of the amount of oxygen used to produce ATP under
normal conditions. To compensate, glycolysis is upregulated,
allowing measurement of maximal production of free protons.
FCCP, an uncoupling agent, abolishes the proton gradient
across the mitochondrial inner membrane leading to
the maximum consumption of oxygen by the mitochon-
dria as the electron transport system attempts to restore
the gradient. Complete inhibition of mitochondrial res-
piration is achieved by blocking complex I (rotenone)
and complex III (antimycin) simultaneously. Under this
condition, the level of non-mitochondrial respiration can
be determined.
Neurites of SCG explant cultures were subjected to these
treatments at two time points: straight after cut (early) and
140 min after cut (late). Neurites that were measured late after
cut showed significantly reduced mitochondrial respiration
(Fig. 1a) and glycolysis (Fig. 1b) under all conditions of the
assay compared to neurites that were measured early after cut.
This finding suggests that reductions in both, mitochondrial
respiration and glycolysis, contribute to the decline in ATP
seen after axonal injury.
As WLDS expression can ameliorate the decline of ATP
levels after axonal injury, we asked whether this is achieved
by maintaining mitochondrial respiration and/or glycolysis.
For this purpose, wild-type andWldS neurites of SCG cultures
were measured late after cut with the same series of treatments
as described above. WldS neurites showed significantly more
oxygen consumption compared to wild-type neurites under
maximal respiration condition. Under basal conditions, a non-
significant trend towards increased oxygen consumption was
also observed (Fig. 2a). Extracellular acidification rates were
significantly increased under conditions of both basal and
maximal glycolysis in cut WldS neurites (Fig. 2b). These
findings suggest that WLDS slows the decline in ATP after
cut by partially maintaining both glycolysis and mitochondrial
respiration, although a block with 2-deoxyglucose would be
required to rule out other causes of the increase in ECAR. No
intrinsic differences in mitochondrial respiration or glycolysis
were observed between WldS and wild-type uncut SCG cul-
tures (data not shown).
WldS neurites can also maintain NAD levels after injury
in vitro (Wang et al. 2005), as can transected nerves in vivo
(Di Stefano et al. 2014). As both glycolysis and mitochondrial
respiration require NAD, we tested whether these changes in
axonal energetics could be explained by changes in NAD
levels. For this, we decreased NAD levels in uncut SCG
explant cultures by adding FK866, an inhibitor of NAMPT,
the rate-limiting enzyme in the NAD salvage pathway, and
subjected them to the assay described above. As expected,
treatment with 100 nMFK866 for 24 h significantly decreased
NAD levels in uncut SCG explants (Fig. 3a), confirming
efficacy of the drug. Uncut SCG cultures treated with
100 nM FK866 remained viable for at least 3 days in culture
(Di Stefano et. al 2014 and data not shown). Oxygen con-
sumption under maximal respiration conditions was signifi-
cantly reduced in uncut FK866-treated SCG neuron cultures
compared to control cultures (Fig. 3b). Extracellular acidifi-
cation rates under conditions of basal and maximal glycolysis
were also significantly reduced in FK866-treated cultures
(Fig. 3c). Thus, lowering NAD levels is sufficient to produce
changes in mitochondrial respiration and glycolysis similar to
those rescued by WLDS after cut.
One question that remains is whether the partial rescue of
mitochondrial respiration and glycolysis in WLDS neurites
underlies the protective phenotype of WLDS. To further in-
vestigate this matter, we used another genetic model to delay
Wallerian degeneration (Sarm1−/−) (Osterloh et al. 2012).
SARM1 is a Toll-like receptor adaptor protein that plays a
role in the innate immune system (Dalod 2007). Recently, it
was discovered that Sarm1 deletion can significantly delay
Wallerian degeneration similar toWLDS (Osterloh et al. 2012;
Gerdts et al. 2013). To investigate whether mitochondrial
respiration and glycolysis are also partially rescued in Sarm1−/−
neurites, we subjected cut Sarm1−/− neurites to the same assay
described above. Sarm1−/− neurites showed no change in oxygen
consumption under basal conditions compared to wild-type
neurites (Fig. 4a) suggesting that rescue of basal mitochondrial
respiration is not necessary to delay Wallerian degeneration.
Interestingly, Sarm1−/− neurites showed an increased maximal
mitochondrial respiration similar to the one seen in WldS
neurites. Extracellular acidification rates were increased relative
to wild-type under both basal and maximal conditions (Fig. 4b)
which was again similar to the observation in WldS
neurites. This indicates that amelioration of defects in
glycolysis may play a role in the protective phenotype
to delay Wallerian degeneration.
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Discussion
This study reports that both mitochondrial respiration and
glycolysis are reduced in neurites after axonal injury, a finding
that could help explain the decline in ATP levels after axonal
injury observed previously (Wang et al. 2005). Thus, a decline
in both mitochondrial respiration and glycolysis appears to
contribute to the reduction in ATP. Although the experiments
reported in Wang et al. (2005) were based on DRG cultures
and we used SCGs, many studies have shown that the WldS
(and Sarm1−/−) phenotype is present in both cell culture sys-
tems (Gilley et al. 2013; Sasaki and Milbrandt 2010; Babetto
et al. 2010; Milde et al. 2013; Gilley and Coleman 2010;
Conforti et al. 2011; Osterloh et al. 2012). WLDS also pre-
serves ATP levels after energy deprivation in cortical neuron
cultures (Shen et al. 2013) and extends neurite survival in
dopaminergic neurons exposed to the mitochondrial toxin
MPP+ (Antenor-Dorsey and O’Malley 2012). Thus, it is likely
that these data are relevant to many neuronal cell types
throughout the central, peripheral and sympathetic nervous
system.
In neurites expressing WLDS, the decline in mitochondrial
respiration and glycolysis was partially ameliorated. This
observation is in line with studies showing that WLDS-ex-
pressing neurites can maintain ATP levels after axonal injury
(Wang et al. 2005). Our results indicate that glycolysis in
particular, and potentially also mitochondrial respiration, con-
tribute to this effect. However, another study suggested that
WLDS expression is not able to slow the rate of a rotenone-
induced reduction in neuronal ATP (Press and Milbrandt
Fig. 1 Mitochondrial respiration and glycolysis both decline after axonal
injury. Oxygen consumption rate (OCR) in pmol/min (a) and extracellu-
lar acidification rate (ECAR) in pmH/min (b) of 6 days in vitro (DIV)
mouse wild-type neurites measured early after cut (square) or late after
cut (circle). Recordings took place under basal, oligomycin-inhibited
(oligomy), FCCP-induced maximal and rotenone+antimycin A-
inhibited (rot/antimy) conditions. *p<0.05, **p<0.01 two-way repeated
measures ANOVA. Data are mean±SEM of n=5 independent experi-
ments for both OCR and ECAR
Fig. 2 WLDS partially rescues
cellular energetics after axonal
injury. OCRs in pmol/min (a) and
ECARs in pmH/min (b) of six
DIV mouse wild-type neurites
(circle) andWldS neurites (square)
measured late after cut. Recordings
took place under basal,
oligomycin-inhibited (oligomy),
FCCP-induced maximal and
rotenone+antimycin A-inhibited
(rot/antimy) conditions. *p<0.05
two-way repeated measures
ANOVA. Data are mean±SEM of
n=6 independent experiments for
both OCR and ECAR
868 J Mol Neurosci (2015) 55:865–871
2008). These contradictory findings may be explained by the
different trigger of axon degeneration in these two studies (i.e.
mitochondrial damage vs axotomy).
We were able to demonstrate that a reduction in NAD
levels is sufficient to reduce cellular energetics. Interestingly,
these changes were similar to those rescued by WLDS after
cut. This suggests that the maintenance of NAD levels inWldS
neurites after axonal injury at least partially contributes to the
maintenance of ATP levels.
NAD is an important redox equivalent in glycolysis as well
as in mitochondrial respiration. Thus, a depletion of cytosolic
NAD caused by FK866 or axonal injury would directly influ-
ence glycolysis. However, the mitochondrial NAD pool is
thought to be independent of the cytosol due to the imperme-
ability of the mitochondrial inner membrane to NAD
(Nikiforov et al. 2011; Di Lisa and Ziegler 2001). NAD is
thought to be synthesised in the mitochondrial matrix by the
mitochondrial specific isoform NMNAT3, using NMN that
enters mitochondria by an unknown mechanism. The exis-
tence of such an isoform has recently been challenged
questioning the local synthesis of NAD in mitochondria
(Felici et al. 2013). Further work aimed at understanding
compartmentalisation and flux of NAD in the cell should
provide valuable insight to test the hypothesis that low NAD
levels contribute to the decline in ATP levels after axonal
injury.
However, the contention that maintenance of NAD levels is
critical for prolonged axon survival in WLDS-expressing neu-
rons is controversial. Exogenous application of NAD (Araki
et al. 2004; Wang et al. 2005; Sasaki et al. 2006) and its
Fig. 3 A reduction in NAD levels decreases cellular energetics. SCG
explants were cultured for five DIV and treated with DMSO or 100 nM
FK866 for 24 h as indicated. a NAD levels normalised to total protein
(n=3 per condition). **p<0.01 (Student’s t test). OCRs in pmol/min (b)
and ECARs in pmH/min (c) of six DIV mouse wild-type SCG explants
treated with DMSO (circle) or with 100 nM FK866 for 24 h (square).
Recordings took place under basal, oligomycin-inhibited (oligomy),
FCCP-induced maximal and rotenone+antimycin A-inhibited (rot/
antimy) conditions. *p<0.05 two-way repeated measures ANOVA. Data
are mean±SEM of n=4 independent experiments for both OCR and
ECAR. Higher OCR and ECAR readings were recorded as cell bodies
were still present in these cultures
Fig. 4 Rescue of basal glycolysis rather than basal mitochondrial respi-
ration may be part of the protective phenotype to delay Wallerian degen-
eration. OCRs in pmol/min (a) and ECARs in pmH/min (b) of six DIV
mouse wild-type neurites (circle) and Sarm1−/− neurites (square) mea-
sured late after cut. Recordings took place under basal, oligomycin-
inhibited (oligomy), FCCP-induced maximal and rotenone+antimycin
A-inhibited (rot/antimy) conditions. *p<0.05, **p<0.01 two-way repeat-
ed measures ANOVA. Data are mean±SEM of n=4 independent exper-
iments for both OCR and ECAR
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precursors such as Nam (Wang et al. 2005), NaMN (Sasaki
et al. 2006), NMN (Sasaki et al. 2006) and NR (Sasaki et al.
2006) led to axonal protection in vitro. In a mouse model of
EAE, application of Nam prevented the degeneration of
demyelinated axons and improved behavioural deficits
(Kaneko et al. 2006). Overexpression of enzymes upstream
of NMNAT2 in the NAD biosynthesis pathway, such as
nicotinic acid phosphoribosyltransferase and NAMPT, also
showed a moderate protective effect in vitro (Sasaki et al.
2006). However, no axon-protective effect was observed
when NAD levels were increased by inhibiting the NAD
hydrolysing enzymes PARP and/or CD38 (Sasaki et al.
2009). It was argued that these contradictory findings reflect
changes in NAD levels in different subcellular compartments
(Wang et al. 2012). Finally, in a recent study, we show that a
rise in the NMNAT substrate NMN is more closely linked to
axon degeneration than a fall in NAD (DiStefano et al. 2014).
With this study, we also tried to address whether partial
rescue of mitochondrial respiration and glycolysis is a
mechanism by which WLDS promotes axon survival. Our
data in another genetic model of delayed Wallerian degen-
eration (Sarm1−/−) indicated that ameliorating the defects
in basal mitochondrial respiration is not necessary to delay
Wallerian degeneration questioning the importance of ATP
generated through mitochondrial respiration for axon sur-
vival. This is in line with a study in flies that mislocalised
axonal mitochondria to the cell body. In this scenario,
WLDS was still able to delay Wallerian degeneration after
axonal injury (Kitay et al. 2013) suggesting that the pro-
tective phenotype is independent of mitochondria. In our
study, we could also demonstrate that the decline in gly-
colysis under basal and maximal conditions was amelio-
rated inWldS and Sarm1−/− neurites. Thus, ATP production
through glycolysis could be an underlying mechanism
promoting axonal survival, but we cannot rule out the
possibility that it is a consequence of survival. A previous
study showed that a reduction in ATP levels by inhibition
of glycolysis does not cause axon degeneration (Press and
Milbrandt 2008) questioning the importance of ATP gen-
erated by glycolysis for axons. A recent study suggested
that neither mitochondrial respiration nor glycolysis is
important to maintain ATP levels after energy deprivation.
Instead, the reverse action of enzymes such as NMNATs
was considered to be important for ATP production after
energy deprivation (Shen et al. 2013).
In this study, we were able to show that cellular energetics
decline within the first 140 min after axonal injury in primary
culture and that WLDS can partially rescue this decline, po-
tentially through maintaining NAD levels. However, it is not
necessary to rescue basal mitochondrial respiration to prolong
the survival of injured axons. Glycolysis, on the other hand,
appears more closely related to survival of these axons. These
findings open new routes to study glycolysis and the
connection between NAD and ATP levels in axon degenera-
tion, which may help to eventually develop therapeutic strat-
egies to treat neurodegenerative diseases.
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